1. Home
  2. Directory
  3. Alabama
  4. Birmingham
  5. Pediatrics
  6. NPI Profile
  7. Prescriptions 1497045587

HEATHER MICHELLE RELYEA ASHLEY M.D.
Prescription History 1497045587
Pediatrics in Birmingham, AL

NPI Status: Active since April 11, 2011

Contact Information

1600 7TH AVE S
BIRMINGHAM, AL
ZIP 35233
Phone: (205) 638-9585
Fax: (205) 975-6503

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for HEATHER MICHELLE RELYEA ASHLEY M.D., an active Pediatrics specialist practicing in Birmingham, AL. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 106 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 62 claims alone.

Medication Index

B
O
P
R
T
No matching medications currently found on file.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 62
30-Day Fills 62.0
Days Supply 1,860
AL State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills98.9
Peer Average Days Supply2,966
Conservative Utilization

This provider writes prescriptions for this formulation 36.1% less frequently than the standard regional baseline metric for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $247,359.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,989.67

State Avg Cost Per Claim

$3,894.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 307
AL State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.1
Peer Average Days Supply194
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.2% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $77.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.08

State Avg Cost Per Claim

$4.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Prezista

Generic Formulation: DarunavirSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
AL State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply915
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,251.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,204.65

State Avg Cost Per Claim

$2,100.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Darunavir belongs to a class of drugs known as protease inhibitors. Darunavir must be given with certain other medications (such as cobicistat, ritonavir) to increase (boost) the levels of darunavir. This helps darunavir work better. Darunavir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. This medication is not recommended for use in children younger than 3 years due to the increased risk of serious side effects.

Ritonavir

Generic Formulation: RitonavirSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
AL State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply980
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $957.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$87.03

State Avg Cost Per Claim

$128.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Ritonavir belongs to a class of drugs known as protease inhibitors. It increases (boosts) the levels of other protease inhibitors, which helps these medications work better. Ritonavir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Tivicay

Generic Formulation: Dolutegravir SodiumSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
AL State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills69.3
Peer Average Days Supply1,999
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.8% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,757.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,250.69

State Avg Cost Per Claim

$2,230.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like HEATHER MICHELLE RELYEA ASHLEY M.D. provides transparency into local medical care patterns within Birmingham, AL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pediatrics** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.